Cogent stockholders approve officer exculpation; annual meeting results filed

Cogent Biosciences, Inc.

Approved amendment to certificate of incorporation to exculpate officers: 86,181,373 for, 4,422,462 against.
Re-elected directors Karen Ferrante (68,418,781 for) and Matthew E. Ros (77,274,345 for).
Ratified PricewaterhouseCoopers as auditor with 101,115,649 votes for.
Advisory vote on executive compensation approved: 89,797,699 for, 808,715 against.
Company presenting at Jefferies Global Healthcare Conference on June 5, 2025 (details in corporate presentation).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.98

Cogent Biosciences, Inc.: Stockholders approved an amendment to the certificate of incorporation to provide for officer exculpation from liability, which was filed and became effective on June 4, 2025 (effective 2025-06-04).

Change: charter amendment
Effective: 2025-06-04

Exact text from the filing

At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to provide for exculpation from liability for officers of the Company, as described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2025 (the “Amendment”). On June 4, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Amendment, which became effective immediately upon such filing.

View on SEC.gov

Browse all governance changes →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-135337

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.